The ethics of phase I trials of biologic agents

被引：2
|
作者：
Hanauer, Stephen B.
机构：
[1] SB Hanauer is Editor-in-Chief of Nature Clinical Practice Gastroenterology & Hepatology.,
来源：
NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY | 2008年 / 5卷 / 10期
关键词：
D O I：
10.1038/ncpgasthep1259
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：533 / 533
页数：1
相关论文
共 50 条
  • [21] The ethics of phase 0 oncology trials
    Abdoler, Emily
    Taylor, Holly
    Wendler, David
    CLINICAL CANCER RESEARCH, 2008, 14 (12) : 3692 - 3697
  • [22] BIOLOGIC RESPONSE-MODIFYING AGENTS - WHAT IS AN APPROPRIATE PHASE-I-II STRATEGY
    CARTER, SK
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1980, 8 (04) : 207 - 210
  • [23] Association of creatine kinase and skin toxicity in phase I trials of anticancer agents
    Garcia, V. Moreno
    Thavasu, P.
    Codesido, M. Blanco
    Molife, L. R.
    Pedersen, J. Vitfell
    Puglisi, M.
    Basu, B.
    Shah, K.
    Iqbal, J.
    de Bono, J. S.
    Kaye, S. B.
    Banerji, U.
    BRITISH JOURNAL OF CANCER, 2012, 107 (11) : 1797 - 1800
  • [24] Phase I and II trials of novel anticancer agents: Endpoints, efficacy and existentialism
    Eisenhauer, EA
    ANNALS OF ONCOLOGY, 1998, 9 : 9 - 9
  • [25] Association of creatine kinase and skin toxicity in phase I trials of anticancer agents
    V Moreno Garcia
    P Thavasu
    M Blanco Codesido
    L R Molife
    J Vitfell Pedersen
    M Puglisi
    B Basu
    K Shah
    J Iqbal
    J S de Bono
    S B Kaye
    U Banerji
    British Journal of Cancer, 2012, 107 : 1797 - 1800
  • [26] Ethics and Clinical Research: Improving Transparency and Informed Consent in Phase I Oncology Trials
    Frankel, Paul H.
    Groshen, Susan
    Beumer, Jan H.
    Cleveland, Laura
    Kim, Edward S.
    Karp, Judith E.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (12) : 2155 - +
  • [27] Phase I Trials
    Shader, Richard I.
    CLINICAL THERAPEUTICS, 2014, 36 (04) : 459 - 459
  • [28] Early clinical trials of chemopreventive and biologic agents: Designs, populations and endpoints
    Keegan, P
    Loughman, BE
    UROLOGY, 2001, 57 (4A) : 216 - 219
  • [29] SEAMLESS PHASE I/II ADAPTIVE DESIGN FOR ONCOLOGY TRIALS OF MOLECULARLY TARGETED AGENTS
    Wages, Nolan A.
    Tait, Christopher
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2015, 25 (05) : 903 - 920
  • [30] Evaluation of drug reactions to anti-neoplastic agents in Phase I clinical trials
    Bupathi, M.
    Hajjar, J.
    Hess, K.
    Bean, S.
    Karp, D.
    Meric-Bernstam, F.
    Naing, A.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 136 - 136
12345